{"id":728194,"date":"2023-02-02T08:24:02","date_gmt":"2023-02-02T13:24:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-present-at-the-svb-securities-global-biopharma-conference\/"},"modified":"2023-02-02T08:24:02","modified_gmt":"2023-02-02T13:24:02","slug":"ac-immune-to-present-at-the-svb-securities-global-biopharma-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-present-at-the-svb-securities-global-biopharma-conference\/","title":{"rendered":"AC Immune to Present at the SVB Securities Global Biopharma Conference"},"content":{"rendered":"
\n

\n AC Immune <\/strong>
\n to Present at the <\/strong>
\n SVB Securities Global Biopharma Conference<\/strong>\n <\/p>\n

\n Lausanne, Switzerland,<\/strong>
\n Februar<\/strong>
\n y 2<\/strong>
\n ,<\/strong>
\n 202<\/strong>
\n 3<\/strong> \u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the SVB Securities Global Biopharma Conference, which is taking place virtually from February 14 \u2013 16, 2023.<\/p>\n

During the fireside chat, AC Immune\u2019s CEO Dr. Andrea Pfeifer will provide an overview of the company\u2019s precision medicine approach and pipeline, which includes 16 therapeutic and diagnostic programs collectively designed to shift the neurodegenerative disease treatment paradigm towards earlier diagnosis and disease prevention. Dr. Pfeifer will also discuss the company\u2019s wholly-owned anti-amyloid beta vaccine, ACI-24.060, which recently showed positive initial <\/a>interim <\/a>safety and immunogenicity<\/a> in patients with Alzheimer\u2019s disease in the Phase 1b\/2 ABATE trial.<\/p>\n

The fireside chat will take place on February 14, 2023, at 8:40 AM ET \/ 2:40 PM CET. A webcast of the fireside chat will be available on the\u00a0Events Page<\/a>\u00a0of AC Immune\u2019s website. Following the fireside chat, a replay will be archived in the same location.<\/p>\n

\n About AC Immune SA <\/strong>
\n
AC Immune SA\u00a0is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer\u2019s disease, Parkinson\u2019s disease, and NeuroOrphan indications driven by misfolded proteins. The Company\u2019s two clinically validated technology platforms, SupraAntigen\u00ae<\/sup>\u00a0and Morphomer\u00ae<\/sup>, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3.\u00a0AC Immune\u00a0has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including\u00a0Genentech, a member of the Roche Group, Eli Lilly and Company, and\u00a0others, resulting in substantial non-dilutive funding to advance its proprietary programs and >$3\u00a0billion\u00a0in potential milestone payments.<\/p>\n

SupraAntigen\u00ae\u00a0is a registered trademark of\u00a0AC Immune SA\u00a0in the following territories: AU, EU, CH, GB, JP, RU, SG and\u00a0USA. Morphomer\u00ae is a registered trademark of\u00a0AC Immune SA\u00a0in CN, CH, GB, JP, KR, NO and RU.<\/p>\n

The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.<\/p>\n

\n For further information, please contact:<\/strong>\n <\/p>\n\n\n\n
\n Head of <\/strong>
\n Investor Relations<\/strong>
\n & Corporate Communications<\/strong>
\n
Gary Waanders, Ph.D., MBA
AC Immune
Phone: +41 21 345 91 91
Email: gary.waanders@acimmune.com<\/a><\/p>\n<\/td>\n		\n U.S. Investors<\/strong>
\n
Corey Davis, Ph.D.
LifeSci Advisors
Phone: +1 212 915 2577
Email: cdavis@lifesciadvisors.com<\/a><\/p>\n<\/td>\n<\/tr>\n
\n International Media<\/strong>
\n
Chris Maggos
Cohesion Bureau
Phone: +41 79 367 6254
Email: chris.maggos@cohesionbureau.com<\/a><\/p>\n<\/td>\n		\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n Forward looking statements<\/strong>
\n
This press release contains statements that constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune\u2019s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cpotential,\u201d \u201coutlook\u201d or \u201ccontinue,\u201d and other comparable terminology. Forward-looking statements are based on management\u2019s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions \u201cItem 3. Key Information \u2013 Risk Factors\u201d and \u201cItem 5. Operating and Financial Review and Prospects\u201d in AC Immune\u2019s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.<\/p>\n

\n

\n Attachment<\/strong>\n <\/p>\n